

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

Fig. 1 ACA Activity Effect of Serum vs Fish Gelatin




FIGURE 1




FIGURE 2





FIGURE 3




FIGURE 4

Serum Crossreactivity of ACA 6626-403 Peptide




FIGURE 5




FIGURE 6

# ACA ELISA of Purified Ab fr. Serum 6501




FIGURE 7



### 6501 G-Track of Random Clones

2<sup>nd</sup> Round 3<sup>rd</sup> Round 4<sup>th</sup> Round 5<sup>th</sup> Round c1c2




FIGURE 8




FIGURE 9

Phage ELISA w/ 6501 Mollr Phage 11.9.93




FIGURE 10

Inhibition of (3B10)4 / 6501 Derived by 6501  
Derived Peptide Monomer with 400 Diluted  
Ser.6501




FIGURE 11

Inhibition of Cdl-2.3%Hu Ser.(no IgG) by  
Modified Peptides 3G3 with 400x Diluted  
Serum 6501




FIGURE 12

# Inhibition of (3B10)4 / 6501 Derived by Truncated or Non-Truncated 3B10 with 400 Diluted Serum 6501




FIGURE 13

# Effect of Peptide on the Inhibition of (3B10)4 / 6501 Derived by Alpha MeP 3B10 Monomer with 400 Diluted Serum 6501




FIGURE 14

# Cross reactivity of peptide LJP 688 with aff-ACA

Cardiolipin/ $\beta$ 2-GPI-coated plates




FIGURE 15



LJP 685-MTU-DABA-PEG (COMPOUND 36)





Figure 16

LJP 685-ATU-MTU-AHAB-TEG (COMPOUND 35)



Treatment groups. Concentration of tolerogen in dish. \* P=0.0001

Figure 17

# DS-G3C Solution Structure

CLGVLA~~K~~LC




Figure 18

# Solution Structures of Lead ACA Peptides: Cyclic Nine Residue Peptides




Figure 19

# Pharmacophore for binding to anti-cardiolipin antibodies, based on solution structure of DS3G3c (CLGVLA<sup>K</sup>LC) and alanine scanning of this peptide

Amino or other positively charged group

$$D(1,2) = 22^\circ$$




Figure 20A




Figure 20B

# Inhibition of $\beta_2$ GP-1 by 6501-Derived Peptides with 350x Diluted Serum 6501




FIGURE 21

6701 Titration of CB2\*-F:  
(FITC)-GPCILLARDRCG-CO<sub>2</sub><sup>-</sup>




FIGURE 22

6501 Titration of CB2\*-F:  
(FITC)-GPCILLARDRCG-CO<sub>2</sub><sup>-</sup>




FIGURE 23



6501 Titration of CB2\*-F:  
(FITC)-GPCILLARDRCG-CO<sub>2</sub><sup>-</sup>




FIGURE 24

Displacement of CB2\*-F from  
6701 using 1.04 eq. of CB2\*:  
GPCILLARDRCG-CO<sub>2</sub><sup>-</sup>




FIGURE 25

CB2\* Titration of CB2\*-F/6701:  
CB2\*: GPCILLARDRCG-CO<sub>2</sub><sup>-</sup>




FIGURE 26

3B10 Titration of CB2\*-F/6701:  
3B10: AGPCLLLAPDRCPG-CO<sub>2</sub><sup>-</sup>




FIGURE 27




FIGURE 28




FIGURE 29




FIGURE 30




FIGURE 31






FIGURE 32